Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FL-SSTR2
- Development stage
- Preclinical
- Lead developer
- Full-Life Technologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FL-SSTR2 is a preclinical radionuclide drug conjugate (RDC) developed by Full Life Technologies, targeting the somatostatin receptor 2 (SSTR2). SSTR2 is a well-validated target in nuclear medicine, frequently overexpressed in neuroendocrine tumors (NETs) and other malignancies such as small cell lung cancer (SCLC) and certain breast cancers. FL-SSTR2 utilizes the company's proprietary UniRDC platform to conjugate a high-affinity SSTR2-targeting ligand with a therapeutic radioisotope. The mechanism involves the specific binding of the conjugate to SSTR2 on the tumor cell surface, followed by internalization and the delivery of localized ionizing radiation, which induces lethal DNA damage in the cancer cells. This targeted approach aims to provide potent anti-tumor activity while sparing non-target tissues.
- Other names
- FL-SSTR2-Full Life Technologies-SSTR2-RDC (Radionuclide Drug Conjugate)-NETs (Neuroendocrine Tumors)-SCLC (Small Cell Lung Cancer)-BC (Breast Cancer)
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on FL-SSTR2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FL-SSTR2.